IHME Intelligence Prototype

Asbestos Burden and Evidence Atlas

This prototype turns the IHME ecosystem into a single visual story: where asbestos-related diseases hit hardest, where exposure-linked burden persists, and where the world is still under-observed. The current dataset is a synthesis scaffold designed to accept official IHME exports from GBD Results, GBD Sources, and related visualization tools.

Priority Disease Mesothelioma

Primary view currently driving the atlas state.

Blind-Spot Countries 0

Countries with evidence-gap score above the global alert threshold.

People Outside Coverage 0

Population living outside the inferred reporting coverage represented here.

Most Exposed Storyline -

Country combining high burden intensity with thin source support.

What is official

Disease burden structure is modeled on IHME GBD Results outputs and source metadata patterns from the GBD Sources Tool.

What is inferred

The evidence coverage score and uncovered-population estimate are prototype metrics derived from source count, recency, uncertainty, and population exposure.

What this becomes

A production-grade atlas once official IHME exports are dropped into the same JSON schema.

Global Atlas

Burden, Evidence, and Blind Spots

Switch the disease lens, choose the map mode, and compare the world’s burden against the strength of the observed evidence underneath it.

World Map

Mesothelioma burden intensity

Lower
Higher

Country Spotlight

Select a country

Click any mapped country to see its burden pattern, source environment, and likely weak points in the evidence chain.

Burden -
Coverage -
Gap Score -
Last Input Year -
0 /100

Evidence Coverage Score

Why this country matters

The atlas will surface a narrative here based on burden trajectory, source support, and uncovered population risk.

Signal Space

Burden vs. Coverage

Upper-left is the danger zone: high burden with low evidence coverage. Bubble size reflects uncovered population.

Blind Spot Ranking

Where the world is least observed

This ranking is intentionally ruthless: it prioritizes burden, uncertainty, recency, and the share of population outside inferred source coverage.

Trend Theater

Selected country trajectory

Four anchor years show how the burden story changed from 1990 to 2021 under the selected disease lens.

IHME Surface Map

Where each layer comes from

Method

How the evidence-gap layer is simplified

Important: The blind-spot score and coverage score shown on this site are prototype composite indicators created for exploratory visualization. They are not official IHME metrics.
Prototype demo formula: gap score = 0.35 × burden percentile + 0.25 × uncovered population share + 0.20 × uncertainty + 0.10 × source staleness + 0.10 × source sparsity

In production, burden values should come directly from IHME GBD exports, while evidence context should be refreshed from the GBD Sources Tool, Epi Visualization, mortality tools, and country profile context. This prototype deliberately separates direct indicators from inferred scores so the simplifications remain visible.

What Is Official vs. Inferred

The intended official inputs for this atlas are IHME burden estimates, IHME source metadata, and IHME uncertainty outputs. By contrast, the coverage score, blind-spot score, and uncovered population share shown in this prototype are inferred constructs created for this website.

  • Official or intended official inputs: GBD burden estimates, source metadata, uncertainty intervals.
  • Inferred prototype inputs: coverage score, blind-spot score, uncovered population share, and weighting scheme.
  • These inferred metrics are visual aids for exploration, not formal IHME indicators.

Why These Weights Were Used

The weights 0.35 / 0.25 / 0.20 / 0.10 / 0.10 were judgment-based design choices. They were chosen to emphasize disease burden first, then population potentially outside observed coverage, then uncertainty, with smaller penalties for older and sparser source environments.

These weights were not copied from IHME and do not represent an endorsed methodology from IHME, WHO, OECD, or any other institution. They were informed by general guidance on composite indicators and health data quality, especially the principle that weighting should follow an explicit conceptual framework and that weights often reflect analytic judgment rather than objective truth.

Assumptions

  • Higher estimated burden should increase priority even when evidence quality varies.
  • Larger uncovered population share may indicate greater risk of under-observation.
  • Greater uncertainty can act as a caution signal for weaker or less stable evidence environments.
  • Older source inputs reduce confidence in how current the evidence picture is.
  • Fewer available sources may indicate thinner evidence support, while not measuring quality directly.
  • Combining these dimensions into one score is useful for communication, even though it compresses complexity.

Possible Limitations

  • The blind-spot score is not an official IHME indicator.
  • The weighting scheme is heuristic and judgment-based.
  • Different weighting choices could materially change the rankings.
  • Uncertainty is an imperfect proxy for evidence weakness.
  • Source count does not equal source quality.
  • Population outside reported coverage is an inferred approximation, not a universal observed statistic.
  • Country-level averages may hide important subnational asbestos hotspots.
  • This visualization should identify questions and priorities, not make definitive claims about surveillance adequacy.

Why These Simplifications Are Used

These simplifications are acceptable for an exploratory dashboard because the aim is to help users detect patterns, compare places, and identify where deeper evidence review may be warranted. They are not a substitute for formal methodological reporting, and this site should always label the evidence-gap layer as experimental, inferred, or prototype.

References

The choice of weights in this prototype is an inference informed by these general methodological references. It is not a published rule from any of the sources above.

Disclaimers

  • This website is an exploratory data-visualization prototype and is provided for informational purposes only.
  • This website does not provide medical advice, diagnosis, treatment advice, legal advice, occupational safety advice, or regulatory advice.
  • The blind-spot score, coverage score, uncovered population share, and related rankings are inferred prototype metrics created for this site and are not official IHME outputs.
  • References to IHME sources describe data inputs or methodological inspiration and do not imply endorsement, review, certification, or affiliation by IHME.
  • Results shown here should not be used as the sole basis for clinical decisions, legal claims, compensation claims, regulatory enforcement, investment decisions, or public policy decisions.
  • No representation or warranty is made that the visualizations are complete, current, error-free, or fit for any particular purpose.
  • Users should verify all important findings against original IHME materials and other authoritative sources before relying on them.
  • Country-level values may conceal important subnational differences, missing populations, or data limitations.
  • By using this site, users accept that exploratory rankings and summaries may change as methods, weights, assumptions, or source data are updated.